Core Viewpoint - Amneal Pharmaceuticals reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.15 per share, and showing an increase from $0.14 per share a year ago, indicating a 40% earnings surprise [1][2] Financial Performance - The company posted revenues of $695.42 million for the quarter ended March 2025, which was 2.71% below the Zacks Consensus Estimate, but an increase from $659.19 million year-over-year [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Amneal shares have declined approximately 2.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $767.5 million, and for the current fiscal year, it is $0.68 on revenues of $3.03 billion [7] - The outlook for the Medical - Drugs industry, where Amneal operates, is favorable, ranking in the top 26% of over 250 Zacks industries, suggesting potential for outperformance [8]

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly a ...

Shares of Verrica Pharmaceuticals Inc. (VRCA) have been struggling lately and have lost 15.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors. Like every technical indicator ...

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Event Participation - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference [1] - The conference will take place from April 7-10, 2025, with Verrica's session scheduled for April 8, 2025, at 1:30 pm ET [2] - Participants can access a live webcast of the event through Verrica's website, with a replay available for 90 days post-event [2]

Core Viewpoint - Verrica Pharmaceuticals has appointed Dr. Noah L. Rosenberg as Chief Medical Officer, aiming to enhance its clinical programs and establish YCANTH as the standard treatment for molluscum contagiosum [1][2]. Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its flagship product YCANTH being the first FDA-approved treatment for molluscum contagiosum [8]. - YCANTH is a drug-device combination product that effectively treats a highly contagious skin disease affecting approximately 6 million people in the U.S., primarily children [7][8]. Appointment of Chief Medical Officer - Dr. Noah L. Rosenberg brings over 30 years of experience in clinical and therapeutic development, having held senior positions in various biotechnology companies [2]. - His previous roles include Chief Medical Officer at Travere Therapeutics and Medimetriks Pharmaceuticals, where he led the development and approval of significant dermatological products [2]. Financial Incentives - As part of his appointment, Dr. Rosenberg was granted a stock option award to purchase 325,000 shares of Verrica's common stock at an exercise price of $0.5221 per share [3][5]. - The stock option will vest over time, with specific conditions tied to Dr. Rosenberg's continued service with the company [6]. Product Development and Market Potential - YCANTH has shown positive results in clinical trials, demonstrating safety and efficacy for treating molluscum contagiosum, with approximately 225 million lives eligible for insurance coverage [7]. - The company is also developing treatments for common warts and has a licensing agreement with Lytix Biopharma to develop VP-315 for non-melanoma skin cancers [8].

Core Viewpoint - Verrica Pharmaceuticals has appointed Dr. Noah L. Rosenberg as Chief Medical Officer to enhance its drug development efforts, particularly for YCANTH® and other clinical-stage programs [2][8]. Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its flagship product YCANTH® being the first FDA-approved treatment for molluscum contagiosum [8]. - The company is also working on treatments for common warts and has a licensing agreement with Lytix Biopharma AS for developing VP-315 for non-melanoma skin cancers [8]. Appointment of Chief Medical Officer - Dr. Noah L. Rosenberg brings over 30 years of experience in clinical and therapeutic development, having held senior positions in various biotechnology companies [2][8]. - His previous roles include Chief Medical Officer at Travere Therapeutics and Medimetriks Pharmaceuticals, where he led the development of significant products [2][8]. - The appointment is seen as a strategic move to advance Verrica's clinical programs and establish YCANTH® as a standard treatment for molluscum contagiosum [2][8]. Stock Option Grant - In connection with Dr. Rosenberg's appointment, he was granted a stock option award to purchase 325,000 shares of Verrica's common stock at an exercise price of $0.5221 per share [3][5]. - The stock option will vest over time, contingent on his continuous service with the company [5][6]. Product Information - YCANTH® is a proprietary drug-device combination product that effectively treats molluscum contagiosum, impacting approximately six million people in the U.S., primarily children [7][8]. - The product is available for $25 per treatment, with financial assistance options for patients in need [7].

Group 1 - Ocular Therapeutix reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.24, representing an earnings surprise of -20.83% [1] - The company posted revenues of $17.08 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 2.40%, and showing an increase from $14.8 million in the same quarter last year [2] - Ocular Therapeutix shares have declined approximately 16.4% since the beginning of the year, contrasting with the S&P 500's gain of 1.2% [3] Group 2 - The earnings outlook for Ocular Therapeutix is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.27 on revenues of $16.79 million, and -$1.05 on revenues of $70.1 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the bottom 48% of over 250 Zacks industries, suggesting potential underperformance compared to the top 50% of ranked industries [8]